Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma

Abstract Glioblastoma (GBM) is a highly aggressive, infiltrative malignancy that cannot be completely cured by current treatment modalities, and therefore requires more precise molecular subtype signatures to predict treatment response for personalized precision therapy. Expression subtypes of GBM s...

Full description

Bibliographic Details

Published in:	Scientific Reports
Main Authors:	Dongdong Luo, Aiping Luo, Su Hu, Ganwei Ye, Dan Li, Hailin Zhao, Biao Peng
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-07-01
Subjects:	Glioblastoma Molecular subtype Biomarkers Precision medicine Immunotherapy Drug therapy
Online Access:	https://doi.org/10.1038/s41598-024-68648-5